Ozempic for Adults 65 and Older: Complete Caregiver Administration Guidance

Print or save as PDF

See the public record for Semaglutide

Does Ozempic need a different dose at 65 or older?

No. Ozempic is a GLP-1 receptor agonist injected once weekly [1]. Its labeled uses are glycemic control in adults with type 2 diabetes, reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. There is no weight-loss indication on the Ozempic label [1].

The label's geriatric section answers the age question directly. In the pooled placebo- and active-controlled glycemic control trials, 744 Ozempic-treated patients (23.6%) were 65 or older [1]. In SUSTAIN 6, the cardiovascular outcomes trial, 788 Ozempic-treated patients (48%) were 65 or older and 157 (9.6%) were 75 or older. The label reports no overall differences in safety or efficacy between these patients and younger ones, adding that greater sensitivity of some older individuals cannot be ruled out [1].

The label lists no age-based dose change and recommends no dose adjustment for renal impairment. It still warns about acute kidney injury from volume depletion after gastrointestinal reactions and recommends monitoring renal function during initiation and dose escalation when those reactions occur [1].

The weekly injection: four rules the label sets

• Timing. The Ozempic label specifies one injection each week on the same day, at any time, with or without meals [1].
• Appearance. The label says the solution should appear clear and colorless, and that Ozempic should not be used if particulate matter or coloration is seen [1].
• Site. The label specifies subcutaneous injection in the abdomen, thigh or upper arm, with a different injection site each week when injecting in the same body region [1].
• Sharing. An Ozempic pen must never be shared between patients, even if the needle is changed, because of the risk of transmitting blood-borne pathogens [1].

When Ozempic is given alongside insulin, the label says to give them as separate injections and never mix them; they may be injected in the same body region, but should not be adjacent [1].

The titration order, and what happens if a week is missed

The Ozempic label lists a starting dosage of 0.25 mg once weekly for 4 weeks, followed by 0.5 mg once weekly. The 0.25-mg dosage is not a maintenance dosage. Further steps, if additional glycemic control is needed, are 1 mg once weekly after at least 4 weeks on 0.5 mg and then 2 mg once weekly after at least 4 weeks on 1 mg; the maximum is 2 mg once weekly [1]. For the kidney indication, the label increases the dosage to 1 mg once weekly after at least 4 weeks on 0.5 mg [1].

The Ozempic label directs that a missed dose be given within 5 days of the day it was due; after that, the dose is skipped and the next one goes on the usual day [1]. The injection weekday can be changed as long as the two doses are more than 48 hours apart [1].

What nausea and vomiting looked like in the trials

In the pooled placebo-controlled Ozempic trials in type 2 diabetes (262 patients on placebo, 260 on 0.5 mg, 261 on 1 mg, mean 32.9 weeks), nausea occurred in 6.1%, 15.8% and 20.3%; vomiting in 2.3%, 5% and 9.2%; diarrhea in 1.9%, 8.5% and 8.8%; abdominal pain in 4.6%, 7.3% and 5.7%; and constipation in 1.5%, 5% and 3.1% [1]. Any gastrointestinal reaction was reported in 15.3%, 32.7% and 36.4%, and 0.4%, 3.1% and 3.8% stopped treatment for GI reasons [1]. The label reports that most nausea, vomiting and diarrhea reports occurred during dose escalation [1].

The mean age in that pool was 56 and 3.4% were 75 or older [1], so these trial rates describe the study population and may not predict an individual older adult's experience.

Dehydration and the kidneys

Most reported cases of acute kidney injury in people taking Ozempic occurred after nausea, vomiting or diarrhea led to dehydration, and some cases required hemodialysis [1]. The label says to monitor renal function in patients reporting these reactions, especially during initiation and dose escalation [1].

FLOW tested Ozempic in kidney disease: 3,533 adults with type 2 diabetes and chronic kidney disease took Ozempic 1 mg weekly or placebo, with median follow-up of 3.4 years. The composite of kidney failure, a 50% or greater fall in eGFR, or kidney or cardiovascular death occurred in 18.7% on semaglutide versus 23.2% on placebo (HR 0.76, 95% CI 0.66 to 0.88) [2].

Low blood sugar when insulin or a sulfonylurea is in the mix

Semaglutide stimulates insulin release in the presence of elevated blood glucose, and the label says combining it with an insulin secretagogue such as a sulfonylurea, or with insulin, raises the risk of hypoglycemia including severe hypoglycemia [1]. The label notes that hypoglycemia was more frequent when Ozempic was used with a sulfonylurea, and advises considering a reduction in the insulin or secretagogue dose when Ozempic is started, plus teaching patients the signs and symptoms [1].

In the monotherapy trial, documented symptomatic hypoglycemia at a 70 mg/dL threshold occurred in 0%, 1.6% and 3.8% on placebo, 0.5 mg and 1 mg, with no severe episodes in any arm. Added to basal insulin with or without metformin, the documented symptomatic rates were 15.2% on placebo, 16.7% on 0.5 mg and 29.8% on 1 mg, with severe episodes in 0%, 0% and 1.5% [1].

Warnings in the Ozempic label

• Pancreatitis. The label asks that patients be watched for persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and says to discontinue Ozempic if pancreatitis is suspected [1].
• Gallbladder disease. If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1].
• Allergic reactions. Anaphylaxis and angioedema have been reported. The label says to discontinue Ozempic if a hypersensitivity reaction occurs, treat promptly, and monitor until signs and symptoms resolve [1].
• Thyroid C-cell tumors. The boxed warning asks that patients be told the symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, shortness of breath and persistent hoarseness [1].
• Eye changes. In a 2-year trial in type 2 diabetes with high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% on Ozempic versus 1.8% on placebo, and 8.2% versus 5.2% among those with retinopathy at baseline. Patients with a history of diabetic retinopathy should be monitored for progression [1].
• Procedures and anesthesia. Pulmonary aspiration has been reported in people receiving GLP-1 receptor agonists during elective surgeries or procedures under general anesthesia or deep sedation [1].
• Stomach and bowel. Ozempic is not recommended in patients with severe gastroparesis, and postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1].